ECOR
electroCore, Inc. NASDAQ Listed Jun 22, 2018$6.29
Mkt Cap $50.8M
52w Low $4.16
47.5% of range
52w High $8.64
50d MA $6.59
200d MA $5.75
P/E (TTM)
-4.0x
EV/EBITDA
-3.5x
P/B
—
Debt/Equity
-5.5x
ROE
817.2%
P/FCF
-4.6x
RSI (14)
—
ATR (14)
—
Beta
0.60
50d MA
$6.59
200d MA
$5.75
Avg Volume
60.3K
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
200 Forge Way · Rockaway, NJ 07866 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.59 | -0.59 | +0.0% | 6.66 | -1.1% | -5.9% | — | — | — | — | — |
| Mar 19, 2026 | AMC | -0.35 | -0.34 | +2.9% | 6.56 | -2.3% | -4.7% | -6.6% | -5.9% | +2.0% | -8.2% | — |
| Nov 5, 2025 | AMC | -0.36 | -0.40 | -11.1% | 4.74 | +4.9% | +23.2% | +23.0% | +31.2% | +32.9% | +27.8% | — |
| Aug 6, 2025 | AMC | -0.32 | -0.35 | -9.4% | 6.93 | -17.6% | -29.1% | -33.3% | -37.8% | -35.4% | -25.8% | — |
| May 7, 2025 | AMC | -0.56 | -0.47 | +16.1% | 6.81 | -14.8% | -23.8% | -31.7% | -29.2% | -30.7% | -32.3% | — |
| Mar 12, 2025 | AMC | -0.34 | -0.40 | -17.6% | 13.00 | -9.8% | -26.5% | -34.2% | -36.5% | -35.5% | -38.4% | — |
| Nov 13, 2024 | AMC | -0.29 | -0.31 | -6.9% | 13.40 | -12.3% | +1.5% | -18.4% | -28.0% | -24.7% | -25.8% | — |
| Aug 7, 2024 | AMC | -0.39 | -0.38 | +2.6% | 6.10 | +3.8% | -1.3% | -7.4% | -0.7% | -3.4% | -2.1% | — |
| May 8, 2024 | AMC | -0.50 | -0.53 | -6.0% | 7.24 | +1.4% | -5.4% | -5.5% | +0.1% | +3.6% | +2.2% | — |
| Mar 13, 2024 | AMC | -0.55 | -0.61 | -10.9% | 6.45 | -3.7% | -5.6% | +2.9% | +8.5% | +7.4% | -1.2% | — |
| Nov 8, 2023 | AMC | -0.64 | -0.68 | -6.2% | 5.77 | +9.4% | +2.8% | -0.5% | -2.9% | +0.2% | +8.0% | — |
| Aug 9, 2023 | AMC | -1.00 | -1.03 | -3.0% | 5.43 | -5.0% | -8.8% | -9.6% | -9.4% | -6.4% | -12.2% | — |
| May 3, 2023 | AMC | -1.00 | -1.24 | -24.0% | 6.00 | -0.7% | -5.0% | -4.0% | +0.8% | +0.3% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.41 | -0.8% | +9.1% | +5.5% | -2.9% | -5.0% | -10.8% |
| Mar 13 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $13.00 | $11.73 | -9.8% | -26.5% | -34.2% | -36.5% | -35.5% | -38.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $11.73 | -9.8% | -26.5% | -34.2% | -36.5% | -35.5% | -38.4% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $14.73 | +5.7% | +11.1% | +4.2% | +9.6% | +25.8% | +16.7% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.45 | $6.21 | -3.7% | -5.6% | +2.9% | +8.5% | +7.4% | -1.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.63 | $6.97 | +5.1% | +9.0% | +11.3% | +12.2% | +13.9% | +12.2% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.77 | $6.31 | +9.4% | +2.8% | -0.5% | -2.9% | +0.2% | +8.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.43 | $5.16 | -5.0% | -8.8% | -9.6% | -9.4% | -6.4% | -12.2% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $5.96 | -0.7% | -5.0% | -4.0% | +0.8% | +0.3% | -4.5% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $7.16 | +3.6% | -4.6% | -1.3% | -3.3% | -0.9% | -2.6% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.36 | $12.00 | -2.9% | -16.3% | -18.5% | -25.0% | -21.0% | -17.2% |
| Aug 14 | BTIG | Upgrade | Neutral → Buy | — | $33.90 | $34.80 | +2.7% | +0.4% | -4.9% | -6.6% | -11.5% | -14.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.90 | $34.80 | +2.7% | +0.4% | -4.9% | -6.6% | -11.5% | -14.6% |
| Mar 24 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $7.05 | $6.90 | -2.1% | -4.3% | -8.5% | -1.0% | -14.0% | +157.4% |
| Nov 14 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $27.75 | $22.05 | -20.5% | -20.0% | -14.6% | -25.9% | -15.7% | -18.4% |
| Nov 14 | JMP Securities | Downgrade | Outperform → Market Perform | — | $27.75 | $22.05 | -20.5% | -20.0% | -14.6% | -25.9% | -15.7% | -18.4% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $79.95 | $75.75 | -5.3% | -29.6% | -28.9% | -43.7% | -41.5% | -41.3% |
| May 15 | BTIG Research | Downgrade | Buy → Neutral | — | $79.95 | $75.75 | -5.3% | -29.6% | -28.9% | -43.7% | -41.5% | -41.3% |
No insider trades available.
8-K · 2.02
!! High
electroCore, Inc. -- 8-K 2.02: Earnings Results
electroCore reported earnings results showing operational performance changes, though specific financial metrics require reviewing the attached press release exhibit for investor impact assessment.
May 6
8-K
Unknown — 8-K Filing
ElectroCore's 27% revenue growth to $32.0 million in 2025 demonstrates strong market traction for its neuromodulation devices, making it attractive to investors seeking biotech exposure with proven commercial momentum.
Mar 19
Data updated apr 25, 2026 6:22am
· Source: massive.com